Abstract
BackgroundN6-methyladenosine (m6A) is the most abundant modification in mRNA of humans. Emerging evidence has supported the fact that m6A is comprehensively involved in various diseases especially cancers. As a crucial reader, YTHDF2 usually mediates the degradation of m6A-modified mRNAs in m6A-dependent way. However, the function and mechanisms of m6A especially YTHDF2 in prostate cancer (PCa) still remain elusive.MethodsTo investigate the functions and mechanisms of YTHDF2 in PCa, in vitro, in vivo biofunctional assays and epigenetics experiments were performed. Endogenous expression silencing of YTHDF2 and METTL3 was established with lentivirus-based shRNA technique. Colony formation, flow cytometry and trans-well assays were performed for cell function identifications. Subcutaneous xenografts and metastatic mice models were combined with in vivo imaging system to investigate the phenotypes when knocking down YTHDF2 and METTL3. m6A RNA immunoprecipitation (MeRIP) sequencing, mRNA sequencing, RIP-RT-qPCR and bioinformatics analysis were mainly used to screen and validate the direct common targets of YTHDF2 and METTL3. In addition, TCGA database was also used to analyze the expression pattern of YTHDF2, METTL3 and the common target LHPP in PCa, and their correlation with clinical prognosis.ResultsThe upregulated YTHDF2 and METTL3 in PCa predicted a worse overall survival rate. Knocking down YTHDF2 or METTL3 markedly inhibited the proliferation and migration of PCa in vivo and in vitro. LHPP and NKX3–1 were identified as the direct targets of both YTHDF2 and METTL3. YTHDF2 directly bound to the m6A modification sites of LHPP and NKX3–1 to mediate the mRNA degradation. Knock-down of YTHDF2 or METTL3 significantly induced the expression of LHPP and NKX3–1 at both mRNA and protein level with inhibited phosphorylated AKT. Overexpression of LHPP and NKX3–1 presented the consistent phenotypes and AKT phosphorylation inhibition with knock-down of YTHDF2 or METTL3. Phosphorylated AKT was consequently confirmed as the downstream of METTL3/YTHDF2/LHPP/NKX3–1 to induce tumor proliferation and migration.ConclusionWe propose a novel regulatory mechanism in which YTHDF2 mediates the mRNA degradation of the tumor suppressors LHPP and NKX3–1 in m6A-dependent way to regulate AKT phosphorylation-induced tumor progression in prostate cancer. We hope our findings may provide new concepts of PCa biology.
Highlights
N6-methyladenosine (m6A) is the most abundant modification in messenger RNA (mRNA) of humans
The survival probability was analyzed in 497 patients, and the result revealed that a poorer survival rate was along with a higher expression level of YTHDF2 in prostate cancer (PCa) patients (P = 0.0396) (Fig. 1d)
As the crucial m6A writer, METTL3 was upregulated in TCGA PCa tissues (n = 498) compared to the normal controls (n = 52) (P < 0.001) (Fig. 1f) and in several cohorts from Oncomine, and there is an increasing tendency of METTL3 expression was associated with higher Gleason scores (Fig. 1g)
Summary
N6-methyladenosine (m6A) is the most abundant modification in mRNA of humans. Emerging evidence has supported the fact that m6A is comprehensively involved in various diseases especially cancers. YTHDF2 usually mediates the degradation of m6A-modified mRNAs in m6A-dependent way. The function and mechanisms of m6A especially YTHDF2 in prostate cancer (PCa) still remain elusive. N6-methyladenosine (m6A) as the most abundant modification in messenger RNA (mRNA) of humans is a reversible process promoted by ‘writers’, inhibited by ‘erasers’ and functionally executed by readers [1, 2]. The modified m6A sites are recognized and executed by variable readers to produce different functions or events. Emerging evidence indicates that m6A is involved in various biological or physiological processes, and several disorders especially variable tumors [10,11,12]. It’s more convincing that the significant role of m6A modification is a new epigenetics concept known as “RNA epigenetics” or “epi-transcriptomics” to explain traditional problems in a novel way
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.